Dermatology

Distinguishing biologic-eligible patients may still need further biomarker and disease severity research.

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

The pivotal phase 3 findings are the largest to assess a systemic pediatric atopic dermatitis treatment, to date.

After decades of development, researchers are nearing clinical trials for immune response-shifting vaccines. Will they be feasible for patients, and accepted by clinicians?

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.

The US Food and Drug Administration has approved minocycline topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgarism in adults and pediatrics patients 9 years of age or older.

The FDA set a 2020 PDUFA action date for FMX103, a topical foam to treat papulopustular rosacea.

New findings from the 12-week pivotal JADE MONO-1 trial show the JAK1 inhibitor's benefit in skin clearance and itch relief.

The data presented at the EADV Congress in Madrid builds on the findings reported at 52 and 64 weeks in the phase 3 reSURFACE 1 and 2 trials.